CD19 and myeloid sarcoma: The prevalence of CD19+CD138- mature B cells was higher in bout-onset MS compared to PPMS and OND and the prevalence of CD19+CD138+ plasma blasts was higher in bout-onset MS and PPMS compared to OND.